Skip to content
akaturk Academic measurement

Article detail · 2023 · article

Real-life data on the comorbidities in spondyloarthritis from our multicenter nationwide registry: BioStar

ISSN2148-5046
YÖKSİS OpenAlex Open access · diamond
Year2023
Citations13OpenAlex
Citations10Semantic Scholar
Percentile%88.7
FWCI2.181.00 = world average
Scopus (SJR)Q3
WoS (JCR)Q4

Data source split

  • YÖKSİSYÖKSİS article record
  • YÖKSİS venueArchives of Rheumatology
  • Catalog match (ISSN)Archives of Rheumatology
  • OpenAlexOpenAlex enrichment (abstract, citations, topics)
  • Semantic Scholarcitation count (not merged with OpenAlex)

Abstract

OpenAlex English

Objectives: Considering that the comorbid situations during the management of Spondyloarthritis (SpA) have been underlined in several recommendations, the main objective of this study was to evaluate the comorbid conditions of Turkish patients with SpA. Patients and methods: This cross-sectional observational study was conducted with 1,242 SpA patients (844 males, 398 females; mean age: 43.9±11.0 years; range, 19 to 81 years) diagnosed according to the modified New York criteria for ankylosing spondylitis or the Assessment of SpondyloArthritis International Society (ASAS) criteria. The patient data were collected from the Biologic and targeted Synthetic antirheumatic drugs Registry (BioStar) between February 1, 2019, and December 29, 2020. Clinical and demographic data, including, age, sex, disease duration, body mass index (BMI), pain, patient’s global assessment, physician’s global assessment, Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Metrology Index, and Maastricht Enthesitis Score, were recorded. Comorbid conditions were recorded by filling out a questionnaire according to the clinical history or medical records. Charlson Comorbidity Index and Rheumatic Disease Comorbidity Index scores were calculated from the gathered comorbidity information. Results: Nine hundred thirteen patients had radiographic axial SpA, 153 had nonradiographic axial SpA, and 176 had peripheral SpA. The most common comorbidities were hypertension (HT) (n=167, 13.4%), diabetes mellitus (DM) (n=83, 6.7%), thyroid disorders (n=64, 5.6%), and depression (n=61, 4.9%). The comorbidities and the calculated comorbidity indices were significantly higher in females, in those with a BMI >25 kg/m2 , and those over 60 years of age. No relationship was found between smoking and alcohol use and comorbidities. A significantly higher prevalence of HT and DM in peripheral SpA patients and a lower prevalence of thyroid disorders in radiographic axial SpA patients were observed. Conclusion: The most commonly reported comorbidities were HT, DM, thyroid disorders, and depression in SpA patients according to the BioStar database. The frequency of comorbidities and composite comorbidity scores were higher among females, older (>60 years) patients, and overweight (BMI >25 kg/m2 ) patients.

Topics

Citations

OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.

13citationsOpenAlex · cited_by_count (cache / database)

11 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).

  1. 2022 Cardiovascular comorbidities in spondyloarthritisCitations 11 · OpenAlex
  2. 2024 Biological treatment in elderly and young patients with ankylosing spondylitis: TURKBIO real-life data resultsCitations 8 · OpenAlex
  3. 2024 Biological treatment in elderly and young patients with ankylosing spondylitis: TURKBIO real-life data resultsCitations 8 · OpenAlex
  4. 2024 Biological treatment in elderly and young patients with ankylosing spondylitis: TURKBIO real-life data resultsCitations 8 · OpenAlex
  5. 2024 Biological Treatment in Elderly and Young Patients with Ankylosing Spondylitis: TURKBIO Real-life Data ResultsCitations 8 · OpenAlex
  6. 2024 Biological treatment in elderly and young patients with ankylosing spondylitis: TURKBIO real-life data resultsCitations 8 · OpenAlex
  7. 2026 Prevalence and risk factors of difficult-to-treat axial spondyloarthritis: Real-life evidence from the BioSTaR databaseCitations 1 · OpenAlex
  8. 2024 Comorbidity Profiles in Inflammatory Rheumatic Diseases: An Analytical PerspectiveCitations 1 · OpenAlex
  9. 2024 Comorbidity Profiles in Inflammatory Rheumatic Diseases: An Analytical PerspectiveCitations 1 · OpenAlex
  10. 2024 Comorbidity Profiles in Inflammatory Rheumatic Diseases: An Analytical PerspectiveCitations 1 · OpenAlex

Authors

14
  1. HASAN FATİH ÇAY SAĞLIK BİLİMLERİ ÜNİVERSİTESİ 1
  2. MELTEM ALKAN MELİKOĞLU 2
  3. FATMA GÜL YURDAKUL 3
  4. HATİCE BODUR 4
  5. ŞEBNEM ATAMAN 5
  6. ERHAN ÇAPKIN 6
  7. GÜLCAN GÜRER 7
  8. İLHAN SEZER AKDENİZ ÜNİVERSİTESİ 8
  9. MEHMET TUNCAY DURUÖZ 9
  10. AYLİN REZVANİ 10
  11. İLKER YAĞCI 11
  12. FERİDE NUR GÖĞÜŞ 12
  13. AYHAN KAMANLI 13
  14. ÖZGÜR AKGÜL 14